The COVID-19 pandemic has stirred up the cannabis market

Faced with the coronavirus pandemic, HempCare decided to partner with the BeHemp foundation to ensure that patients undergoing treatment with cannabis oil are not left without medication during the quarantine period. The BeHemp Foundation is known for treating patients in severe, terminal or chronic conditions.

The possible lack of medication is a concern for mothers, fathers, and caregivers of children who use CBD oil. In addition, the pandemic is stirring up the entire cannabis market.

You can find more information about the cannabis markets and other important news in the cannabis sector with the Hemp.im app. This app collects the latest marijuana news among cannabis sectors that investors operate in.

HempCare will give up profit to make sure patients have access to CBD oil

The company HempCare will pass on to the foundation at cost price, without freight, full-spectrum oils of 1,000 mg and 1,500 mg with values up to 64% lower.

“We were able to make an associative purchase. We filed an injunction to bring all the medications from the US at once, so we saved the freight. We also decided to give up the profit. It’s the least we can do over the next 120 days to make sure patients have access to oil,” said Cristina Taddeo, CEO of HempCare.

The 1,000-milligram, 30-milligram oil, which cost $102 + $23 (R$525 + R$120) in freight, will now cost $46 (R$240), a savings of nearly 64%. The 1,500 mg oil, also of 30 ml, that came out for $153 +$23 (R$790 + R$120) of freight, now costs $72 (R$370), almost 60% cheaper. Patients or guardians can buy the oils with these values starting this Monday, March 23rd, through Dr. Cannabis.

“We will not leave anyone without medicine. Whoever needs it can look for us. We can’t exploit health. Of course, we need profit to pay employees and generate jobs, but not the way the market has done so far,” said the CEO.

Can CBD oil help stop the COVID-19 pandemic?

Professor Saoirse O’Sullivan is the scientific leader of the Association for the Cannabinoid Industry, a new industry body that claims to be committed to promoting a safe, legal and well-regulated CBD market. “I think it’s really dangerous to spread this concept. We cannot imply that cannabinoid products can prevent COVID-19 without any data,” he said.

Doctor Andy Yates agreed: “The evidence for the use of CBD in COVID-19 is as strong as the use of carrots, they do not exist. During a period of great national and international challenges that we face, we as a CBD industry cannot come close to offering false hope.”

“There is no evidence that hemp or CBD improves welfare or health,” O’Sullivan said. “But yes, people will use products that they realize will improve their immune systems or health, like vitamins and supplements.”

Neurosurgeon Pedro Pierro, Brazil’s pre-writer of medical cannabis, said that cannabis can help strengthen the immune system, but warns that the epidemic is on the rise: “Cannabidiol and most cannabinoids can help strengthen the immune system as a whole, but not as a treatment for the coronavirus and there is no medical indication at this time either,” Pierre said.

__

(Featured image by R+R Medicinals via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in SECHAT, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.